Biomira Confirms FDA Panel Review Meeting For TRUQUANT BR Blood Test Kit For Detection of Recurrent Breast Cancer.EDMONTON, Alberta--(BUSINESS WIRE)--Sept. 8, 1995--Biomira Inc. today confirmed the U.S. Food & Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) has scheduled a meeting of the Immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic Devices Advisory Panel to review Biomira Diagnostics Inc.'s Premarket Approval premarket approval Medical devices A scientific and regulatory review by the FDA to ensure the safety and effectiveness of a Class III device, before its approval for marketing. See Advisory panel, Medical device. Application (PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy ) for TRUQUANT(R) BR(TM) blood test kit for detection of recurrent breast cancer. The Panel review is scheduled to take place on September 21, 1995. In April, 1995, the Company announced Biomira Diagnostics Inc., its wholly-owned subsidiary, had filed a PMA with the FDA and that the filing had been accepted on an expedited review status. Biomira is a biotechnology company developing an integrated line of products for the diagnosis and treatment of cancer. CONTACT: Biomira Jane Jack, 403/490-2812 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion